CORSYM
LOE ApproachingNDAORALSUSPENSION, EXTENDED RELEASE
Approved
Jan 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORSYM is an oral extended-release suspension approved in 1984 by UCB Pharma as a small-molecule NDA. The specific indication, mechanism of action, and pharmacologic class are undisclosed in available data. Patient population cannot be characterized without indication details.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling likely downsizing of brand team and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's maturity and approaching LOE; career opportunities are limited and skewed toward defensive roles managing market decline. Professionals considering this assignment should expect transition planning and portfolio rationalization rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on CORSYM at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.